TCB-2

From Wikipedia, the free encyclopedia

TCB-2
Systematic (IUPAC) name
((8R)-4-bromo-2,5-dimethoxy-8-bicyclo[4.2.0]octa-1(6),2,4-trienyl)methanamine
Identifiers
CAS number  ?
ATC code  ?
PubChem 16086382
Chemical data
Formula C11H14BrNO2 
Mol. mass 272.14 g/mol
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status
Routes  ?

TCB-2 or (R)-(4-Bromo-3,6-dimethoxybenzocyclobuten-1-yl)methylamine is a conformationally resticted derivative of the phenethylamine derived hallucinogen 2C-B, discovered in 2006 by a team at Purdue University. It acts as a potent agonist for the 5HT2A and 5HT2C receptors with a Ki of 0.26nM at the human 5HT2A receptor. In drug-substitution experiments in rats, TCB-2 was found to be of similar potency to both LSD and Br-DFLY, ranking it among the most potent phenethylamine hallucinogens yet discovered.[1]

[edit] References

  1. ^ McLean TH, Parrish JC, Braden MR, Marona-Lewicka D, Gallardo-Godoy A, Nichols DE. 1-Aminomethylbenzocycloalkanes: conformationally restricted hallucinogenic phenethylamine analogues as functionally selective 5-HT2A receptor agonists. Journal of Medicinal Chemistry. 2006 Sep 21;49(19):5794-803. PMID 16970404